Semaglutide
A glucagon-like peptide-1 (GLP-1) receptor agonist that influences appetite and glucose signaling.
What this compound is.
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. GLP-1 is an incretin hormone the gut releases after eating; agonists in this class engage its receptors to influence appetite signaling and glucose regulation.
It is among the more extensively studied compounds in this space and is discussed in the specific clinical context of metabolic health rather than in general terms.
How it has been studied.
Neutral notes on how this compound has been studied. These are not claims of safety or effectiveness, and not medical advice.
Studied clinically in the context of metabolic health, glucose regulation, and weight management.
Examined for its effect on appetite and satiety signaling.
Part of a well-characterized incretin (GLP-1) class of compounds.
Format, and what a provider weighs.
Prescribed formulations are typically administered by subcutaneous injection. Form and suitability are a provider's decision — nothing here is a recommendation, a protocol, or a dose.
- A provider reviews your metabolic history, personal and family medical history, and current medications before considering a prescription.
- Not appropriate for everyone; certain personal or family histories are contraindications a provider will screen for.
- Not appropriate during pregnancy or while breastfeeding. Availability varies by state.
Semaglutide cannot be purchased directly on this site. It is available only after a licensed provider evaluates your intake and determines that treatment is clinically appropriate, and it is dispensed by a licensed compounding pharmacy. Eligibility is never guaranteed, and availability varies by state. See how it works and our approach to care.